Jing-Yan Han Selected Research

notoginsenoside R1

1/2021	The Composite of 3, 4-Dihydroxyl-Phenyl Lactic Acid and Notoginsenoside R1 Attenuates Myocardial Ischemia and Reperfusion Injury Through Regulating Mitochondrial Respiratory Chain.
7/2015	QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode.
1/2014	Protective effects of Notoginsenoside R1 on intestinal ischemia-reperfusion injury in rats.
1/2008	Effect of notoginsenoside R1 on hepatic microcirculation disturbance induced by gut ischemia and reperfusion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jing-Yan Han Research Topics

Disease

28	Ischemia 06/2022 - 01/2005
14	Edema (Dropsy) 06/2022 - 04/2012
10	Reperfusion Injury 01/2021 - 08/2009
7	Infarction (Infarctions) 01/2021 - 04/2010
6	Hemorrhage 01/2022 - 03/2015
6	Ischemic Stroke 01/2021 - 10/2012
6	Brain Edema (Cerebral Edema) 01/2021 - 04/2012
6	Fibrosis (Cirrhosis) 01/2019 - 01/2012
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 04/2010
5	Inflammation (Inflammations) 01/2021 - 05/2013
5	Cardiomegaly (Heart Hypertrophy) 01/2021 - 01/2012
5	Cerebral Infarction 01/2020 - 01/2005
5	Coronary Disease (Coronary Heart Disease) 03/2019 - 01/2005
5	Thrombosis (Thrombus) 01/2018 - 01/2006
4	Body Weight (Weight, Body) 01/2022 - 01/2012
4	Myocardial Infarction 02/2019 - 04/2010
4	Neoplasms (Cancer) 01/2019 - 08/2013
4	Lung Injury 01/2018 - 03/2013
3	Hypoxia (Hypoxemia) 01/2022 - 01/2018
3	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2022 - 10/2014
3	Rupture 01/2021 - 09/2013
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 01/2018
3	Fatty Liver 08/2017 - 12/2009
3	Non-alcoholic Fatty Liver Disease 08/2017 - 06/2013
3	Vascular Diseases (Vascular Disease) 12/2009 - 01/2005
2	Stroke (Strokes) 01/2021 - 01/2020
2	Cerebral Hemorrhage 01/2020 - 01/2018
2	Endotoxemia 01/2019 - 10/2013
2	Atherosclerosis 01/2019 - 01/2005
2	Hypertrophy 01/2019 - 01/2016
2	Cognitive Dysfunction 01/2018 - 01/2018
2	Necrosis 01/2018 - 01/2017
2	Hyperlipidemias (Hyperlipidemia) 01/2018 - 01/2008
2	Colitis 01/2017 - 01/2013
2	Acute Lung Injury 12/2016 - 11/2014
2	Hypertension (High Blood Pressure) 01/2016 - 01/2013
2	Brain Ischemia (Cerebral Ischemia) 06/2015 - 10/2012
1	Infections 06/2022

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 06/2022 - 04/2010
14	AlbuminsIBA 06/2022 - 04/2012
11	qishen yiqiIBA 01/2021 - 01/2012
10	Evans Blue (Blue, Evans)FDA Link 01/2021 - 04/2012
8	Adenosine Triphosphate (ATP)IBA 06/2022 - 01/2013
7	Cardiotonic Agents (Cardiac Stimulants)IBA 01/2019 - 01/2005
6	CollagenIBA 01/2019 - 01/2012
6	AntioxidantsIBA 01/2019 - 01/2009
5	Lactic Acid (Lactate)FDA LinkGeneric 01/2021 - 01/2009
5	Claudin-5IBA 01/2021 - 10/2012
5	LipopolysaccharidesIBA 06/2020 - 02/2014
5	Adenosine Monophosphate (AMP)IBA 01/2018 - 01/2013
5	Pharmaceutical PreparationsIBA 01/2018 - 01/2008
5	CytokinesIBA 01/2018 - 10/2014
4	astragaloside AIBA 06/2022 - 11/2013
4	OccludinIBA 01/2022 - 10/2012
4	notoginsenoside R1IBA 01/2021 - 01/2008
4	Adenosine Diphosphate (ADP)IBA 01/2018 - 09/2013
4	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2017 - 01/2013
3	Small Interfering RNA (siRNA)IBA 06/2022 - 08/2013
3	cadherin 5IBA 01/2022 - 01/2017
3	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021 - 01/2018
3	Caveolin 1IBA 01/2021 - 10/2012
3	SirtuinsIBA 01/2021 - 08/2015
3	Peptide Hydrolases (Proteases)FDA Link 01/2020 - 03/2015
3	gualou xiebai baijiutangIBA 03/2019 - 01/2018
3	Insulin (Novolin)FDA Link 01/2019 - 01/2015
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019 - 01/2013
3	salvianolic acidIBA 01/2019 - 11/2010
3	Sirtuin 3IBA 01/2019 - 08/2015
3	src-Family KinasesIBA 01/2018 - 06/2015
3	caffeic acidIBA 09/2015 - 04/2012
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 01/2019
2	Actins (F Actin)IBA 01/2021 - 01/2018
2	Connexin 43 (Connexin43)IBA 01/2021 - 01/2019
2	yi-qi-fu-maiIBA 01/2021 - 09/2009
2	Thrombin FDA Link 01/2020 - 01/2018
2	Therapeutic UsesIBA 02/2019 - 10/2012
2	Triglycerides (Triacylglycerol)IBA 01/2019 - 08/2017
2	oxidized low density lipoproteinIBA 01/2019 - 01/2018
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2019 - 02/2014
2	Hematoxylin (Haematoxylon)IBA 01/2019 - 02/2014
2	Laminin (Merosin)IBA 01/2018 - 12/2016
2	Silybin (Lagosa)IBA 01/2018 - 08/2017
2	Tight Junction ProteinsIBA 01/2017 - 10/2012
2	sym-trinitrobenzeneIBA 01/2017 - 01/2013
2	Sulfonic AcidsIBA 01/2017 - 01/2013
2	Coloring Agents (Dyes)IBA 06/2013 - 04/2012
2	salvianolic acid BIBA 03/2013 - 01/2009
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2013 - 04/2010
2	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 04/2012 - 04/2010
2	Caspase 3 (Caspase-3)IBA 04/2012 - 04/2010
2	Ethanol (Ethyl Alcohol)IBA 12/2009 - 01/2005
2	notoginsenyIBA 12/2009 - 01/2005
2	MyakuryuIBA 01/2008 - 01/2006
1	PowdersIBA 01/2022
1	CateninsIBA 01/2022
1	ClaudinsIBA 01/2022

Therapy/Procedure

10	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 01/2008
7	Therapeutics 01/2021 - 10/2012
2	Drug Therapy (Chemotherapy) 01/2021 - 01/2020
2	Lasers (Laser) 01/2013 - 01/2012